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Background/Purpose: Urinary tract infection (UTI) is the most common bacterial infection in women and
increases in frequency post menopause. Falling oestrogen levels after menopause result in urogenital
atrophy, which can be effectively treated by topical and oral oestrogen therapy. Oestrogen deﬁciency also
results in alteration in vaginal ﬂora and gram-negative faecal colonisation. Together with atrophic
urogenital tissue change, these factors can predispose to ascending UTIs. It is proposed that oestrogen
therapy can restore the normal premenopausal vaginal ﬂora and acidic pH and can improve urogenital
atrophy, prolapse, and cystocele, thus reducing the recurrence rate of UTIs in postmenopausal women.
Methods: A literature search of MEDLINE, EMBASE, PubMed, and CENTRAL was performed for rando-
mised controlled trials in which recurrence of UTI in postmenopausal women for oestrogen versus
placebo or other intervention was the primary outcome.
Results: Five clinical trials and two relevant meta-analyses were identiﬁed. Oestrogen cream was shown
to reduce recurrence of UTI (p< 0.001) similar to oestrogen pessary (p¼ 0.008). Oral oestrogen was less
effective, with only one small trial showing any beneﬁt, with no trend toward beneﬁt with oral oestrogen
on meta-analysis (risk ratio, 1.08; 95% conﬁdence interval, 0.88e1.33). On direct comparison with anti-
biotic prophylaxis, patients receiving antibiotics had signiﬁcantly fewer episodes of symptomatic and
asymptomatic bacteriuria: 0.6 episodes per woman per year instead of 1.6 episodes per woman per year
in those treated with oestrogen.
Conclusion: Oral oestrogen did not reduce the recurrence of UTI and had systemic side effects. There is
evidence to support the use of local oestrogen in the form of a pessary or cream that was generally well
tolerated. However, local oestrogen was not shown to be more effective than oral antibiotic prophylaxis.
Local oestrogen administration, therefore, may play a role where antibiotic therapy cannot be tolerated.
Copyright  2010, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
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Urinary tract infection (UTI) is the most common bacterial
infection in women.1e3 Between 10% and 15% of women older than
60 years have frequent recurrent episodes of urinary infection with
an increasing frequency seen post menopause.1,2 Bacteriuria is also
known to increasewith age. Ten to ﬁfteen percent of 65- to 70-year-
old women have bacteriuria, increasing to 20e50% in women older
than 80 years.1
Epidemiological and clinical studies have investigated factors that
predispose a patient to UTI. Older women also have an increased
incidence of Type 2 Diabetes and reduced inﬂammatory and12 Station Road, Dumbarton,
linical Gerontology & Geriatrics. Pimmunological status. They also have a higher incidence of local
urogenital factors and pelvic ﬂoor dysfunction, which also increase
predisposition to UTI. Oestrogen deﬁciency is known to predispose to
urogenital atrophy.4 Residual volume, reduced urinary ﬂow, previous
urogenital surgery, urinary and faecal incontinence, genital prolapse,
pelvic ﬂoor dysfunction, and cystocele, are all known to be risk factors,
as is urinary incontinence in postmenopausal women.1,4,5 Pelvic ﬂoor
dysfunction also causes urinary and faecal incontinence. Impaired
bladder emptying and reduced urinary ﬂow create a residual volume,
thus predisposing a patient to UTI.4
1.1. Role of oestrogen in continence and development of urogenital
atrophy
The distal vagina and urethra have a rich supply of oestrogen
receptors and have a common embryologic origin.6 They are, there-
fore, subject to similar hormonal inﬂuences.1 In premenopausalublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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environment is a result of the conversion of glucose to lactic acid by
lactobacilli.1
After menopause, oestrogen levels fall; hence, oestrogenic
stimulation of the vaginal epithelium is reduced. This results in
a fall of vaginal glycogen, which is the substrate for lactobacilli.
Consequently, lactobacilli numbers fall, and the vaginal pH rises.1,6
Falling oestrogen levels also result in vaginal epithelial atrophy, and
atrophic changes also affect the urethra and trigone. As a result of
the alteration in ﬂora, gram-negative faecal colonisation of the
vagina may result,6 which, together with the atrophic changes
affecting the urogenital tissues, predispose to ascending UTIs.5,6
Falling oestrogen results in postmenopausal vaginal atrophy.
The clinical features of this are vaginal dryness, itching, irritation,
and dyspareunia.6 In total, more than 50% of women older than 60
years have some degree of urogenital symptoms.1
1.2. Hypothesis of oestrogen in recurrent UTI
Recurrent UTI is deﬁned as three episodes of UTI in 12months or
two episodes in 6 months.5 Long-term, low-dose antimicrobial
therapy reduces the incidence of UTI in women prone to infec-
tions.2 Oestrogen replacement restores the vaginal, urethral, and
trigonal epithelium, and leads to reappearance of the normal
premenopausal vaginal ﬂora.6 Theoretically, therefore, oestrogen
should prevent recurrent UTIs.5,6
Oestrogen can be administered orally or intravaginally and has
been used to treat postmenopausal urogenital disorders. It is
generally felt that low-dose intravaginal oestriol produces a speciﬁc
local urogenital responsewithout inducing substantial endometrial
proliferation and, therefore, can be given without concomitant
progestogen. In elderly patients, this has the advantage of
producing a low incidence of withdrawal bleeding, which is an
unpleasant side effect in this population.6 This literature review
was performed to investigate further the role of oestrogenwith this
theory in mind and to present the clinical trial and meta-analysis
results as an educational resource.
2. Methods
A literature search of MEDLINE (1950 to May 2009), EMBASE
(1980 to May 2009), PubMed, and CENTRAL was performed using
standard methodology and with guidance from the Cochrane
reviewers’ handbook. The search terms were as follows: “Recurrent
Urinary Tract Infection,” “Elderly,” “Post-menopausal,” “Oestrogen”
or “Estrogen,” and “Oestriol” or “Estriol.” The inclusion criterion
were randomised controlled trials (RCTs) with the primary objec-
tive being the reduction of the recurrence rate of UTIs, with any
(oral or topical) oestrogen preparation versus placebo or any other
intervention in postmenopausal women. Therefore, trials where
the primary objective was reducing the recurrence rate of UTI or
time to ﬁrst UTI or reducing the proportion disease free at the end
of the study period were included. Relevant meta-analyses and
review articles were also reviewed for the purposes of this educa-
tional review. Foreign-language trials were excluded from this
review. Forty-two potential studies were identiﬁed, and 30 were
selected as potentially suitable after removal of doubles. After
abstract review, ﬁve RCTs were considered suitable for inclusion.
Additionally, two relevant meta-analyses were included.
3. Results
3.1. Locally administered oestrogen
Raz and Stamm7 evaluated topically applied intravaginal oes-
triol 0.5 mg versus placebo in a randomised, double-blind, placebo-controlled trial of 93 postmenopausal women with recurrent UTI.
The mean age of the treatment group was 64.9 years, and the mean
age of the placebo group was 64.5 years. After 8 months of follow-
up, a reduction of symptomatic and asymptomatic bacteriuria was
detected in the treatment group. UTI rate was 0.5 episodes per
patient per year in the oestriol group versus 5.9 in the placebo
group (p< 0.001). After 4 months, the cumulative likelihood of
remaining disease free was 0.95 in the treatment group compared
with 0.30 in the placebo group. Therefore, more patients remained
free of UTI over the study period.
The effect of oestrogen in the form of an impregnated pessary
ring “Estring” has also been studied in a randomised, open, parallel-
group study.8 The rationale of this type of administration is that
there is high concordance with therapy and controlled local drug
delivery over an extended period. The ring was carried for the 36-
week study period and replaced at 12 and 24 weeks. This trial
included 108 patients at least 2 years post menopause with at least
three symptomatic episodes of presumed UTIs in the last 12
months.
This study quoted substantial rates of reduction in UTI with local
oestrogen. The cumulative likelihood of remaining disease free at
the end of the study period was 45% in the Estring group compared
with 20% in the control group (p¼ 0.008) after 9 months of follow-
up. Fifty-one percent of the oestrogen group had recurrent UTI
during the study period versus 80% of the control group. It should
be noted that, as the patients carried a pessary ring, there is
a potential confounding effect in improving cystocele and prolapse.
Furthermore, only self-reported symptomatic UTIs were recorded;
hence, this study did not quantify nonreported UTIs and asymp-
tomatic bacteriuria. Patients in the control group were untreated,
and in similar trials, there was a reported reduction in UTIs from
pretreatment phases in both treatment and placebo groups because
of close monitoring and early treatment of UTI.
3.2. Sytemically administered oestrogen
Cardozo et al.6 studied the effect of oral oestrogen in a double-
blind, randomised, parallel-group, placebo-controlled trial. Patients
were randomised to receive 3-mg oral oestriol per day or placebo
over a treatment period of 6 months, with 6-month follow-up, with
the primary endpoint being the proportion developing UTI within
the study period.
Forty-three percent of the oestrogen group and 49% of the
placebo group were infection free after 6 months. Overall, oral
oestrogen did not reduce the incidence of urinary symptoms when
compared with placebo.
There was a withdrawal rate of around 30%, mainly because of
comorbidity and mortality. The authors commented on the difﬁ-
culty of conducting research in older patients for this reason. They
also felt that the trial was underpowered, but in any case, there was
no trend toward reduced UTI with oestrogen.
A smaller RCT9 did show some beneﬁt of oral oestrogen. This
was conducted on 40 inpatients and outpatients with a median age
of 78 years. The dose used was 3 mg of oestriol daily for 8 weeks
and 1 mg thereafter. There were 12 weeks of follow-up. In the
patients studied, a statistically signiﬁcant difference was reported
in the second treatment period. There were six UTIs in ﬁve patients
in the oestriol group and 12 UTIs in eight patients in the placebo
group. (p< 0.05).
3.3. Oestrogen versus antibiotics
There has also been a head-to-head trial of vaginal oestrogen
with nitrofurantoin in a double-blind, double-dummy, randomised
trial of 171 patients with a mean age of 68 and 66.9 years in the
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compare the safety and efﬁcacy of both preparations.2 Patients
were randomised to receive a vaginal pessary containing oestriol
and oral placebo capsules or a placebo pessary with oral nitro-
furantoin macrocrystals. The main outcome measure was symp-
tomatic or asymptomatic bacteriuria.
Results showed that after 9 months of follow-up, women
receiving nitrofurantoin macrocystals had signiﬁcantly fewer
episodes of symptomatic and asymptomatic bacteriuria. There
were 1.6 episodes of UTI per woman per year in the oestriol group
versus 0.6 episodes of UTI per woman per year in the nitrofurantoin
group. Overall, 32.6% of the oestriol group and 48.2% of the nitro-
furantoin group were free of bacteriuria at the end of the study
period. The results of the RCT data are presented in summary form
in Table 1.
3.4. Meta-analysis results
This subject has been reviewed on meta-analysis, ﬁrst by Car-
dozo, in an analysis of 345 patients in ﬁve RCTs.10
The authors commented on the difﬁculty of comparing the data
because of the different oestrogen preparations used in the studies.
Analysis showed a risk ratio (RR) reduction of 2.51, with a 95%
conﬁdence interval (CI) of 1.48e4.25. Notably, the Estring trial8 was
included in this analysis, and the conclusion was that oestrogen,
especially with vaginal administration, reduced the recurrence of
UTIs more effectively than the placebo.
The Cochrane Collaboration has also reviewed this subject
recently5 in a meta-analysis of nine studies (3345 postmenopausal
women). The authors concluded that there was signiﬁcant
heterogeneity in the trials, but that, overall, oral oestrogens did not
reduce UTI effectively compared with the placebo (four studies of
2798 women: RR, 1.08; 95% CI, 0.88e1.33). Vaginal oestrogens did
reduce the numbers of UTI effectively compared with placebo, but
this varied according to the type of oestrogen used and the duration
of treatment. This was based mainly on the results of two small
RCTs using different application methods, including the Eriksen
trial.8 The RR for one (cream) was 0.25 (95% CI, 0.13e0.50) and 0.64
(95% CI, 0.47e0.86) for the other (pessary). The second meta-
analysis included the head-to-head Raz trial of oestrogen-con-
taining vaginal pessary use with oral nitrofurantoin macrocrystals.
No subsequent trials were found to investigate the clinical question.
3.5. Secondary outcomes of trials
Most trials also looked at alteration in vaginal pH and found that
oestrogen administered orally or vaginally lowered vaginal pH and
promoted recolonisation by lactobacilli. This has been shown by
a meta-analysis where there was also a nonstatistically signiﬁcant
trend toward reduced recurrent UTI (odds ratio, 1.16; 95% CI,
0.99e1.37).11
Of note, the head-to-head trial versus nitrofurantoin failed to
show any difference in reducing pH or vaginal ﬂora versus antibi-
otics.2 The authors used a pessary rather than cream in this study,
as it is easier to use, especially for older women. The failure of the
pessary to produce changes in the ﬂora or pH supports the
hypothesis that the induced changes in vaginal ﬂora are important
for preventing bacteriuria and may account for the pessary failure
in this particular trial.
There was also a Swedish trial of 41 geriatric inpatients.12 After
1 month of treatment with oral oestriol 3 mg once daily, there was
lactobacilli colonisation. Reduced requirement for antibiotics was
noted as a secondary feature. This trial studied catheterized
patients and showed that those not treated with oestriol were
colonized with faecal-type ﬂora.3.6. Side effects and safety proﬁle
Side effects were reported in most trials, with the exception of
the Kirkengen et al. study.9 Oral oestrogens were generally well
tolerated. There was more association, as one might expect, with
systemic effects. These included nausea, breast tenderness, and
mild vaginal bleeding. On systematic review, it was found that
there were fewer side effects in the placebo group than those in the
oral oestrogen groups overall [RR, 5.11; 95% CI, 1.39e18.76
(p¼ 0.014)].5
Vaginal oestrogen effects included vaginal irritation, burning,
and itching, which was generally mild and self-limiting. No adverse
systemic reactions were reported with vaginal administration.
Eriksen8 also reported vaginal bleeding with the oestrogen-
impregnated pessary ring, nonphysiological discharge, and three
cases of patients requiring pessary removal because of local
discomfort, which was statistically higher in the oestrogen group.
Efﬁcacy and safety were assessed at 1 year, with an overall adverse-
event rate of 6%, including vaginal irritation, ulcers, and vaginal
bleeding, However, patients rated the device highly for
satisfaction.13
In the head-to-head trial of oestrogen versus antibiotics, the
rates of adverse events were similar in both treatment groups.2 As
might be expected, those who had adverse events in the oestrogen
group tended to have local side effects, that is, itching, burning, and
vaginal discharge. The side effects of the nitrofurantoin macro-
crystals were more generalized and varied: fever occurred in ﬁve,
pneumonitis in one, thrombocytopenia in one, urticaria in three,
and gastrointestinal disturbances in two patients.
4. Discussion
Oestrogen has a sound physiological basis for preventing
recurrent UTI.1e5 However, the available evidence does not
consistently show that oestrogen therapy is effective in reducing
recurrence of UTI. These trials are difﬁcult to conduct and are
heterogeneous.5
There is no evidence showing beneﬁt of vaginal oestrogen over
antibiotic prophylaxis, and therefore, it should not be used pref-
erentially over antibiotics.7,8 There is no proven beneﬁt of oral
oestrogen over placebo in reducing recurrent UTI, and it should not
be used in view of the risk of harm.6,9 This may reﬂect the studies
using the wrong dose or the wrong duration of treatment. Addi-
tionally, there is a potential long-term risk of endometrial cancer
with long-term unopposed oestriol. The literature to date shows
better results with vaginal administration of oestrogen, but the
optimum method of delivery and duration remains unclear.5,7,8
Therefore, vaginal oestrogen may have a role where antibiotics
cannot be used. The evidence is stronger for the beneﬁt of cream,7
but in elderly patients, a pessary may be more straightforward to
use. The decision should be made on individual patient basis. There
is evidence for the use of oestrogen in treating vaginal atrophy and
urogenital symptoms, and oestrogen, especially intravaginally, has
a deﬁned role and is commonly used for this reason.4,6,10 The side-
effect proﬁle for antibiotics versus vaginal oestrogen is different,
but there is no evidence to suggest that side effects are less
common with oestrogen.2,5e9
In conclusion, there are few randomised studies addressing the
role of oestrogen in relation to the common problem of UTI. Most of
the studies show that active management of UTIs and encourage-
ment to report symptoms reduce recurrence of UTIs from pretrial
levels. In the elderly, the cause of UTI is complex and multifactorial.
It is difﬁcult to correct for factors, such as urinary incontinence, in
trials, but there is clearly a need for further randomised studies
addressing the role of oestrogen therapy, speciﬁcally in the elderly.
Table 1
Summary table of randomised controlled trial results
Author, year Number of
patients
Oestrogen
preparation
Treatment
period
Follow-up
period
Treatment group
mean age
(range), yr
Control group
mean age
(range), yr
Primary
outcome
p Secondary
outcome
Kirkengen et al., 19929,a 40 Oral oestriol
3 mg daily
12 wk Results reported
at 12 wk
75.4 (61e90) 79.9 (64e91) Oestriol group: 6 UTIs in 5 patients
Placebo: 12 UTIs in 8 patients
<0.05 Reduced vaginal pH
of 6.5e5.5 in oestriol group
Cardozo et al., 19986,a 72 Oral oestriol
3mg daily
6 mo 6 mo 72.5 (60e88) 74.0 (59e91) Cumulative disease free:
Oestrogen: 0.43
Placebo: 0.49
0.65 Decreased urinary
incontinence in oestriol group
Raz and Stamm, 19937,a 93 Intravaginal
cream 0.5 mg
8 mo 4 mo 64.9 (52e81) 64.5 (51e79) Cumulative disease free (at 4 mo):
Oestrogen: 0.95
Placebo: 0.30
<0.001 Oestrogen: lactobacilli
recolonisation
Reduced enterobacteriae
Eriksen, 19998,a 108 Oestrogen
pessary ring
12 wk 24 wk 67 (47e83) 69 (56e87) Cumulative disease free:
Oestrogen: 0.45
Control: 0.20
0.008 Oestrogen: vaginal mucosal
maturation and reduced pH
Raz et al., 20032,a 171 Vaginal pessary vs.
nitrofurantoin
macrocrystals
9 mo Results report-ed
at 9 mo
68 (49e82) 66.9 (46e84) Cumulative disease free:
Oestrogen: 0.32
Nitrofurantoin: 0.48
0.0003 Oestrogen: no lactobacillus
colonisation or reduction in pH
a Included in previous meta-analysis.
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